APEA PMHNP PRE-PREDICTOR EXAM 2026 PSYCHIATRIC-MENTAL
HEALTH NURSE PRACTITIONER EXAM QUESTIONS AND CORRECT
ANSWERS WITH DETAILED RATIONALES FULLY VERIFIED & GRADED A
| COMPREHENSIVE REVIEW COVERING ALL MAJOR PMH TOPICS |
LATEST UPDATE
PART 1: SCIENTIFIC FOUNDATION — NEUROBIOLOGY, PATHOPHYSIOLOGY &
PSYCHOPHARMACOLOGY
Questions 1–50
Q1. A PMHNP is reviewing the neurobiology of major depressive disorder with a
preceptor. The discussion centers on the monoamine hypothesis and
neuroplasticity. Which statement best reflects current understanding of the role
of BDNF in depression pathophysiology?
A. BDNF is decreased in depression and increases with antidepressant treatment
B. BDNF is increased in depression and decreases with treatment
C. BDNF has no role in depression
D. BDNF only affects serotonin levels
Answer: A
Rationale: Brain-derived neurotrophic factor (BDNF) is a neurotrophin critical for
neuronal survival, synaptic plasticity, and neurogenesis. In major depressive
disorder, BDNF levels are decreased in the hippocampus and prefrontal cortex.
Chronic stress reduces BDNF expression. Antidepressant treatment (SSRIs, SNRIs,
TCAs) increases BDNF levels, promoting neuroplasticity and synaptic remodeling.
This supports the neuroplasticity hypothesis of depression, which extends beyond
the monoamine hypothesis. Option B is incorrect because BDNF is decreased, not
increased, in depression. Option C is incorrect because BDNF plays a significant
role. Option D is incorrect because BDNF affects multiple neurotransmitter
systems and neuronal circuits, not just serotonin.
Q2. A patient with schizophrenia presents with prominent auditory hallucinations
and persecutory delusions. Which neurotransmitter abnormality is most directly
associated with these positive symptoms?
A. Decreased serotonin
B. Increased dopamine in the mesolimbic pathway
C. Decreased glutamate in the cortex
D. Increased GABA in the striatum
Answer: B
1
,Rationale: The dopamine hypothesis of schizophrenia posits that positive
symptoms (hallucinations, delusions) are associated with hyperactivity of
dopamine in the mesolimbic pathway. This is supported by the efficacy of
dopamine D2 receptor antagonists (typical antipsychotics) in treating positive
symptoms and the psychotomimetic effects of dopamine agonists (e.g.,
amphetamines). Negative symptoms and cognitive deficits are more closely
associated with dopamine hypofunction in the mesocortical pathway and
glutamate/NMDA receptor hypofunction. Decreased serotonin (A) is more
associated with depression and anxiety. Decreased glutamate (C) contributes to
negative and cognitive symptoms. Increased GABA (D) is not the primary
abnormality in schizophrenia.
Q3. A patient with chronic PTSD is being educated about the HPA axis. Which
statement best describes the HPA axis dysregulation typically seen in PTSD?
A. Increased cortisol levels with enhanced negative feedback
B. Decreased cortisol levels with enhanced negative feedback sensitivity
C. Increased ACTH with decreased cortisol
D. Normal cortisol with no feedback abnormalities
Answer: B
Rationale: In PTSD, the HPA axis often shows decreased basal cortisol levels and
enhanced negative feedback sensitivity, meaning even small amounts of cortisol
suppress ACTH release. This is thought to result from chronic stress-induced
sensitization of glucocorticoid receptors. The CRH (corticotropin-releasing
hormone) system is often upregulated, contributing to hyperarousal symptoms.
Option A is more consistent with major depressive disorder, which often shows
hypercortisolemia and impaired negative feedback. Option C and D do not
accurately describe the typical HPA axis findings in PTSD.
Q4. Which cytochrome P450 enzyme is primarily responsible for the metabolism
of fluoxetine, paroxetine, and many tricyclic antidepressants?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C19
Answer: B
Rationale: CYP2D6 is a highly polymorphic enzyme that metabolizes many
antidepressants, including fluoxetine, paroxetine, venlafaxine, and tricyclic
2
,antidepressants (TCAs). Genetic polymorphisms can lead to poor metabolizer,
intermediate metabolizer, extensive metabolizer, and ultra-rapid metabolizer
phenotypes. Poor metabolizers may experience increased side effects, while
ultra-rapid metabolizers may have reduced efficacy. CYP1A2 (A) metabolizes
olanzapine and clozapine. CYP3A4 (C) metabolizes many benzodiazepines,
carbamazepine, and some antipsychotics. CYP2C19 (D) metabolizes citalopram
and escitalopram.
Q5. A patient is prescribed clozapine. Which hematologic monitoring parameter is
mandatory?
A. Platelet count
B. Absolute neutrophil count (ANC)
C. Hemoglobin
D. Prothrombin time
Answer: B
Rationale: Clozapine carries a boxed warning for severe neutropenia and
agranulocytosis, with a risk of approximately 1–2%. Mandatory monitoring
includes baseline ANC and weekly ANC for the first 6 months, then every 2 weeks
for the next 6 months, and monthly thereafter. If ANC falls below 1,500/µL,
clozapine must be interrupted. Platelet count (A), hemoglobin (C), and PT (D) are
not the primary monitoring parameters for clozapine, though a CBC with
differential is obtained. Other clozapine monitoring includes metabolic
parameters (weight, glucose, lipids) and myocarditis screening.
Q6. Which antipsychotic has the highest risk of extrapyramidal symptoms (EPS)?
A. Clozapine
B. Olanzapine
C. Haloperidol
D. Quetiapine
Answer: C
Rationale: Haloperidol is a high-potency typical antipsychotic with a high risk of
EPS, including acute dystonia, akathisia, parkinsonism, and tardive dyskinesia. This
is due to strong dopamine D2 receptor blockade in the nigrostriatal pathway.
Atypical antipsychotics (clozapine, olanzapine, quetiapine) have lower EPS risk
due to their serotonin-dopamine antagonism (SDA) profile, which includes 5-HT2A
blockade that modulates dopamine release in the striatum. Clozapine (A) has the
lowest EPS risk. Olanzapine (B) and quetiapine (D) have low-to-moderate EPS risk.
3
, Q7. A patient on lithium has a serum level of 1.8 mEq/L. Which clinical
manifestation is most consistent with this level?
A. No symptoms
B. Mild tremor and nausea
C. Coarse tremor, ataxia, and confusion
D. Seizures and coma
Answer: C
Rationale: Lithium therapeutic range is 0.6–1.2 mEq/L. Levels of 1.5–2.0 mEq/L
represent moderate toxicity, with symptoms including coarse tremor, ataxia,
confusion, nausea, vomiting, and diarrhea. Levels above 2.0 mEq/L indicate
severe toxicity, with seizures, coma, and renal failure (D). Levels of 1.0–1.5 mEq/L
may cause mild tremor and nausea (B). No symptoms (A) would be expected at
therapeutic levels. Management of moderate toxicity includes holding lithium,
hydration, and monitoring renal function.
Q8. Which medication requires monitoring of serum drug levels due to a narrow
therapeutic index?
A. Sertraline
B. Lithium
C. Fluoxetine
D. Bupropion
Answer: B
Rationale: Lithium has a narrow therapeutic index (0.6–1.2 mEq/L) and requires
regular serum level monitoring to ensure efficacy and prevent toxicity. Other
psychotropic drugs requiring therapeutic drug monitoring include valproic acid,
carbamazepine, lamotrigine (in some cases), clozapine (for ANC, not drug level),
and tricyclic antidepressants (for some patients). SSRIs (sertraline, fluoxetine) and
bupropion do not require routine serum level monitoring due to their wide
therapeutic index.
Q9. A patient on valproic acid should be monitored for which serious adverse
effect?
A. Hepatotoxicity
B. Nephrotoxicity
C. Ototoxicity
D. Cardiotoxicity
4
HEALTH NURSE PRACTITIONER EXAM QUESTIONS AND CORRECT
ANSWERS WITH DETAILED RATIONALES FULLY VERIFIED & GRADED A
| COMPREHENSIVE REVIEW COVERING ALL MAJOR PMH TOPICS |
LATEST UPDATE
PART 1: SCIENTIFIC FOUNDATION — NEUROBIOLOGY, PATHOPHYSIOLOGY &
PSYCHOPHARMACOLOGY
Questions 1–50
Q1. A PMHNP is reviewing the neurobiology of major depressive disorder with a
preceptor. The discussion centers on the monoamine hypothesis and
neuroplasticity. Which statement best reflects current understanding of the role
of BDNF in depression pathophysiology?
A. BDNF is decreased in depression and increases with antidepressant treatment
B. BDNF is increased in depression and decreases with treatment
C. BDNF has no role in depression
D. BDNF only affects serotonin levels
Answer: A
Rationale: Brain-derived neurotrophic factor (BDNF) is a neurotrophin critical for
neuronal survival, synaptic plasticity, and neurogenesis. In major depressive
disorder, BDNF levels are decreased in the hippocampus and prefrontal cortex.
Chronic stress reduces BDNF expression. Antidepressant treatment (SSRIs, SNRIs,
TCAs) increases BDNF levels, promoting neuroplasticity and synaptic remodeling.
This supports the neuroplasticity hypothesis of depression, which extends beyond
the monoamine hypothesis. Option B is incorrect because BDNF is decreased, not
increased, in depression. Option C is incorrect because BDNF plays a significant
role. Option D is incorrect because BDNF affects multiple neurotransmitter
systems and neuronal circuits, not just serotonin.
Q2. A patient with schizophrenia presents with prominent auditory hallucinations
and persecutory delusions. Which neurotransmitter abnormality is most directly
associated with these positive symptoms?
A. Decreased serotonin
B. Increased dopamine in the mesolimbic pathway
C. Decreased glutamate in the cortex
D. Increased GABA in the striatum
Answer: B
1
,Rationale: The dopamine hypothesis of schizophrenia posits that positive
symptoms (hallucinations, delusions) are associated with hyperactivity of
dopamine in the mesolimbic pathway. This is supported by the efficacy of
dopamine D2 receptor antagonists (typical antipsychotics) in treating positive
symptoms and the psychotomimetic effects of dopamine agonists (e.g.,
amphetamines). Negative symptoms and cognitive deficits are more closely
associated with dopamine hypofunction in the mesocortical pathway and
glutamate/NMDA receptor hypofunction. Decreased serotonin (A) is more
associated with depression and anxiety. Decreased glutamate (C) contributes to
negative and cognitive symptoms. Increased GABA (D) is not the primary
abnormality in schizophrenia.
Q3. A patient with chronic PTSD is being educated about the HPA axis. Which
statement best describes the HPA axis dysregulation typically seen in PTSD?
A. Increased cortisol levels with enhanced negative feedback
B. Decreased cortisol levels with enhanced negative feedback sensitivity
C. Increased ACTH with decreased cortisol
D. Normal cortisol with no feedback abnormalities
Answer: B
Rationale: In PTSD, the HPA axis often shows decreased basal cortisol levels and
enhanced negative feedback sensitivity, meaning even small amounts of cortisol
suppress ACTH release. This is thought to result from chronic stress-induced
sensitization of glucocorticoid receptors. The CRH (corticotropin-releasing
hormone) system is often upregulated, contributing to hyperarousal symptoms.
Option A is more consistent with major depressive disorder, which often shows
hypercortisolemia and impaired negative feedback. Option C and D do not
accurately describe the typical HPA axis findings in PTSD.
Q4. Which cytochrome P450 enzyme is primarily responsible for the metabolism
of fluoxetine, paroxetine, and many tricyclic antidepressants?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C19
Answer: B
Rationale: CYP2D6 is a highly polymorphic enzyme that metabolizes many
antidepressants, including fluoxetine, paroxetine, venlafaxine, and tricyclic
2
,antidepressants (TCAs). Genetic polymorphisms can lead to poor metabolizer,
intermediate metabolizer, extensive metabolizer, and ultra-rapid metabolizer
phenotypes. Poor metabolizers may experience increased side effects, while
ultra-rapid metabolizers may have reduced efficacy. CYP1A2 (A) metabolizes
olanzapine and clozapine. CYP3A4 (C) metabolizes many benzodiazepines,
carbamazepine, and some antipsychotics. CYP2C19 (D) metabolizes citalopram
and escitalopram.
Q5. A patient is prescribed clozapine. Which hematologic monitoring parameter is
mandatory?
A. Platelet count
B. Absolute neutrophil count (ANC)
C. Hemoglobin
D. Prothrombin time
Answer: B
Rationale: Clozapine carries a boxed warning for severe neutropenia and
agranulocytosis, with a risk of approximately 1–2%. Mandatory monitoring
includes baseline ANC and weekly ANC for the first 6 months, then every 2 weeks
for the next 6 months, and monthly thereafter. If ANC falls below 1,500/µL,
clozapine must be interrupted. Platelet count (A), hemoglobin (C), and PT (D) are
not the primary monitoring parameters for clozapine, though a CBC with
differential is obtained. Other clozapine monitoring includes metabolic
parameters (weight, glucose, lipids) and myocarditis screening.
Q6. Which antipsychotic has the highest risk of extrapyramidal symptoms (EPS)?
A. Clozapine
B. Olanzapine
C. Haloperidol
D. Quetiapine
Answer: C
Rationale: Haloperidol is a high-potency typical antipsychotic with a high risk of
EPS, including acute dystonia, akathisia, parkinsonism, and tardive dyskinesia. This
is due to strong dopamine D2 receptor blockade in the nigrostriatal pathway.
Atypical antipsychotics (clozapine, olanzapine, quetiapine) have lower EPS risk
due to their serotonin-dopamine antagonism (SDA) profile, which includes 5-HT2A
blockade that modulates dopamine release in the striatum. Clozapine (A) has the
lowest EPS risk. Olanzapine (B) and quetiapine (D) have low-to-moderate EPS risk.
3
, Q7. A patient on lithium has a serum level of 1.8 mEq/L. Which clinical
manifestation is most consistent with this level?
A. No symptoms
B. Mild tremor and nausea
C. Coarse tremor, ataxia, and confusion
D. Seizures and coma
Answer: C
Rationale: Lithium therapeutic range is 0.6–1.2 mEq/L. Levels of 1.5–2.0 mEq/L
represent moderate toxicity, with symptoms including coarse tremor, ataxia,
confusion, nausea, vomiting, and diarrhea. Levels above 2.0 mEq/L indicate
severe toxicity, with seizures, coma, and renal failure (D). Levels of 1.0–1.5 mEq/L
may cause mild tremor and nausea (B). No symptoms (A) would be expected at
therapeutic levels. Management of moderate toxicity includes holding lithium,
hydration, and monitoring renal function.
Q8. Which medication requires monitoring of serum drug levels due to a narrow
therapeutic index?
A. Sertraline
B. Lithium
C. Fluoxetine
D. Bupropion
Answer: B
Rationale: Lithium has a narrow therapeutic index (0.6–1.2 mEq/L) and requires
regular serum level monitoring to ensure efficacy and prevent toxicity. Other
psychotropic drugs requiring therapeutic drug monitoring include valproic acid,
carbamazepine, lamotrigine (in some cases), clozapine (for ANC, not drug level),
and tricyclic antidepressants (for some patients). SSRIs (sertraline, fluoxetine) and
bupropion do not require routine serum level monitoring due to their wide
therapeutic index.
Q9. A patient on valproic acid should be monitored for which serious adverse
effect?
A. Hepatotoxicity
B. Nephrotoxicity
C. Ototoxicity
D. Cardiotoxicity
4
